Free accessBrief reportFirst published online 2008-6
Effect of Olanzapine and Risperidone on Subjective Well-Being and Craving for Cannabis in Patients with Schizophrenia or Related Disorders: A Double-Blind Randomized Controlled Trial
To examine whether subjective well-being and craving for cannabis were different in patients with schizophrenia or related disorders treated with either olanzapine or risperidone.
Method:
A 6-week, double-blind, randomized trial of olanzapine and risperidone was carried out in 128 young adults with recent onset schizophrenia or related disorders. Primary efficacy measures were the mean baseline-to-endpoint change in total scores on the Subjective Well-Being under Neuroleptics scale, the Obsessive–Compulsive Drug Use Scale, the Drug Desire Questionnaire, and the cannabis use self-report. An analysis of covariance was used to test between-group differences.
Results:
Estimated D2 receptor occupancy did not differ between olanzapine (n = 63) and risperidone (n = 65). Similar improvements in subjective well-being were found in both groups. In the comorbid cannabis-using group (n = 41, 32%), a similar decrease in craving for cannabis was found in both treatment conditions.
Conclusions:
Both olanzapine and risperidone were associated with improved subjective well-being. No evidence was found for a differential effect of olanzapine or risperidone on subjective experience or on craving for cannabis in dosages leading to comparable dopamine D2 occupancy.
Objectif:
Examiner si le bien-être subjectif et l'état de manque de cannabis étaient différents chez les patients souffrant de schizophrénie ou de troubles connexes traités à l'olanzapine ou à la rispéridone.
FentonWSBlylerCRHeinssenRK. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull. 1997;23:637–651.
2.
Van PuttenTMayPRMarderSRSubjective response to antipsychotic drugs. Arch Gen Psychiatry. 1981;38:187–190.
3.
LambertMSchimmelmannBGKarowASubjective well-being and initial dysphoric reaction under antipsychotic drugs—concepts, measurement and clinical relevance. Pharmacopsychiatry. 2003;36:181–190.
4.
NaberDKarowALambertM.Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl. 2005;427:29–34.
5.
ColdhamELAddingtonJAddingtonD.Medication adherence of individuals with first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286–290.
6.
BuhlerBHambrechtMLofflerWPrecipitation and determination of the onset and course of schizophrenia by substance abuse—a retrospective and prospective study of 232 population-based first illness episodes. Schiz Res. 2002;54(3):243–251.
7.
LambertMConusPLubmanDIThe impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005;112:141–148.
8.
de HaanLLavalayeJLinszenDSubjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000;157:1019–1020.
9.
de HaanLvan BruggenMLavalayeJSubjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: A randomized, double-blind study. Am J Psychiatry. 2003;160:303–309.
10.
KapurSSeemanP.Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158:360–369.
11.
NaberDMoritzSLambertMImprovement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79–88.
12.
MueserKTYarnoldPRLevinsonDFPrevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophr Bull. 1990;16:31–56.
13.
FowlerILCarrVJCarterNTPatterns of current and life-time substance use in schizophrenia. Schizophr Bull. 1998;24:443–455.
14.
RegierDAFramerMERaeDSComorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. JAMA. 1990;264:2511–2518.
15.
SoykaMAlbusMKathmannNPrevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci. 1993;242:362–372.
16.
CleghornJMKaplanRDSzechtmanBSubstance abuse and schizophrenia: Effect on symptoms but not on neurocognitive function. J Clin Psychiatry. 1991;52:26–30.
17.
NegreteJCKnappWPDouglasDECannabis affects the severity of schizophrenic symptoms: Results of a clinical survey. Psychol Med. 1986;16:515–520.
18.
LinszenDDingemansPMLeniorME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51:273–279.
19.
DixonLHaasGWeidenPAcute effects of drug abuse in schizophrenic patients: Clinical observations and patients' self-reports. Schizophr Bull. 1990;16:69–79.
20.
PeraltaVCuestaMJ. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand. 1992;85:127–130.
21.
BrownESNejtekVAPerantieDCCocaine and amphetamine use in patients with psychiatric illness: A randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol. 2003;23(4):384–388.
22.
McEvoyJPFreudenreichOLevinEDHaloperidol increases smoking in patients with schizophrenia. Psychopharmacology. 1995;119:124–126.
23.
de HaanLBooijJLavalayeJOccupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. Psychopharmacology. 2006;183:500–505.
24.
McEvoyJFreudenreichOMcGeeMClozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry. 1995;37:550–552.
25.
GreenAIZimmetSVStrousRDClozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?Harv Rev Psychiatry. 1999;6:287–296.
26.
HutchisonKEWoodenASwiftRMOlanzapine reduces craving for alcohol: A DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology. 2003;28:1882–1888.
27.
HutchisonKERutterMCNiauraROlanzapine attenuates cue-elicited craving for tobacco. Psychopharmacology. 2004;175:407–413.
28.
KampmanKMPettinatiHLynchKGA pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 2003;70:265–273.
29.
SayersSLCampbellECKondrichJCocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis. 2005;193:379–386.
30.
SmelsonDALosonczyMFDavisCWRisperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry. 2002;47:671–675.
31.
SmelsonDAWilliamsJZiedonisDA double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat. 2004;27(1):45–49.
32.
NaberD.A self-rating to measure subjective effects of neuroleptic drugs, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10:133–138.
33.
De HaanLWeisfeltMDingemansPMPsychometric properties of the subjective wellbeing under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology. 2002;162:24–28.
34.
FrankenIHHendriksaVMvan den BrinkW.Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict Behav. 2002;27:675–685.
35.
De La GarzaRNewtonTFKalechsteinAD. Risperidone diminishes cocaine-induced craving. Psychopharmacology. 2005;178:347–350.
36.
SmelsonDAZiedonisDWilliamsJThe efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: A preliminary report. J Clin Psychopharmacol. 2006;26:9–12.
37.
HutchisonKASwiftRRohsenowDJOlanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology. 2001;155:27–34.
